High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis
| Autor: | Emanuele Durante-Mangoni, Margaret M. Hannan, Ralph Corey, Paolo Grossi, Athanasios Skoutelis, Vivian H. Chu, Claudio Querido Fortes, Francisco Nacinovich, Thomas L. Holland, Vance G. Fowler, Lawrence P. Park, José M. Miró, Manuela Carugati, Armênio Costa Guimarães, Nuria Fernández-Hidalgo, Arnold S. Bayer, Ru San Tan |
|---|---|
| Přispěvatelé: | Carugati, M, Bayer, A, Miró, Jm, Park, Lp, Guimarães, Ac, Skoutelis, A, Fortes, Cq, DURANTE MANGONI, Emanuele, Hannan, Mm, Nacinovich, F, Fernández Hidalgo, N, Grossi, P, Tan, R, Holland, T, Fowler VG, Jr, Corey, Rg, Chu, V. H. |
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Staphylococcus aureus Clinical Therapeutics Enterococcus faecalis Daptomycin Internal medicine medicine Endocarditis Humans Pharmacology (medical) Prospective Studies Prospective cohort study Adverse effect Aged Pharmacology biology business.industry Endocarditis Bacterial biochemical phenomena metabolism and nutrition Middle Aged medicine.disease biology.organism_classification bacterial infections and mycoses Surgery Anti-Bacterial Agents Infectious Diseases Infective endocarditis Bacteremia Cohort lipids (amino acids peptides and proteins) Female business medicine.drug |
| Zdroj: | Antimicrobial agents and chemotherapy. 57(12) |
| ISSN: | 1098-6596 |
| Popis: | The use of daptomycin in Gram-positive left-sided infective endocarditis (IE) has significantly increased. The purpose of this study was to assess the influence of high-dose daptomycin on the outcome of left-sided IE due to Gram-positive pathogens. This was a prospective cohort study based on 1,112 cases from the International Collaboration on Endocarditis (ICE)-Plus database and the ICE-Daptomycin Substudy database from 2008 to 2010. Among patients with left-sided IE due to Staphylococcus aureus , coagulase-negative staphylococci, and Enterococcus faecalis , we compared those treated with daptomycin (cohort A) to those treated with standard-of-care (SOC) antibiotics (cohort B). The primary outcome was in-hospital mortality. Time to clearance of bacteremia, 6-month mortality, and adverse events (AEs) ascribable to daptomycin were also assessed. There were 29 and 149 patients included in cohort A and cohort B, respectively. Baseline comorbidities did not differ between the two cohorts, except for a significantly higher prevalence of diabetes and previous episodes of IE among patients treated with daptomycin. The median daptomycin dose was 9.2 mg/kg of body weight/day. Two-thirds of the patients treated with daptomycin had failed a previous antibiotic regimen. In-hospital and 6-month mortalities were similar in the two cohorts. In cohort A, median time to clearance of methicillin-resistant S. aureus (MRSA) bacteremia was 1.0 day, irrespective of daptomycin dose, representing a significantly faster bacteremia clearance compared to SOC (1.0 versus 5.0 days; P < 0.01). Regimens with higher daptomycin doses were not associated with increased incidence of AEs. In conclusion, higher-dose daptomycin may be an effective and safe alternative to SOC in the treatment of left-sided IE due to common Gram-positive pathogens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|